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with the catheter channel and was printed with 20% infill 
percentage. The test configurations had the radiochromic slit 
at 6.3 mm distance from the center of the catheter channel 
and were printed with 20% (Test 1) and 40% (Test 2) infill 
percentage. Physical quality of ABS plastic were evaluated by 
analyzing the depth dose profiles measured by Gafchromic 
EBT3 films (International Specialty Products, Wayne, NJ) 
when the 192Ir source passing through the catheter channel 
delivered 2 Gy at 10 mm distance from the axis of the 
channel (Fig.1a).  
Four skin mould applicators with 4 parallel catheter channels 
of 2.5 mm diameters, 5 mm distance between the axis of the 
channel and the surface, and 10 mm distance between 
consecutive channel axes were 3D-printed. Two geometrical 
shapes were compared to the commercial Freiburg Flap 
applicator (Nucletron, Stockholm, SE, Fig. 1b): a group of 16 
semi-spheres reproducing the actual Freiburg geometry 
printed at 10% infill percentage (Fig.1c) and a parallelepiped 
applicator with 10%, 20% and 40% infill printing percentage 
(Fig.1d). A prescription dose of 2 Gy to the surface at 5 mm 
distance from the channels axes was delivered using an 192Ir 
source. Surface dose distributions were measured with 
Gafchromic EBT3 films for both the 3D-printed skin mould 
applicators and the commercial Freiburg Flap applicator 
considered as reference. The gamma index method with dose 
difference (DD) criteria of 3%, distance-to-agreement criteria 
(DTA) of 3 mm and 10% dose threshold was evaluated. 
 
 
 
Results: The radiation attenuation profiles were comparable 
in all the cylindrical configurations. Dose attenuation were 
not sensitive to the density of the material (Tab.1a). When 
comparing 3D-printed skin mould applicators with 
commercial Freiburg Flap in terms of gamma index analysis, a 
high pass rates >90% was obtained. Therefore, the isodose 
overlay and linear dose profiles of film measured using 3D 
printed applicator and commercial Freiburg were in close 
agreement (Tab.1b). 
 
 
Conclusion: ABS3D-printed applicators are a reliable solution 
for patient-specific HDR-BRT of superficial lesions. Further 
assessment of 3D printing techniques and materials are 
required for clinical development.  
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Purpose or Objective: Local residual disease occurs in 7-13 % 
after primary treatment for nasopharyngeal carcinoma (NPC). 
To prevent tumor progression and/or distant metastasis, 
treatment is indicated. This studies focus on the application 
of 3D-CT based and endoscopical guided brachytherapy for 
the treatment of residual lesion in nasopharyngeal cavity of 
NPC after the radical external beam radiotherapy and to 
assess the safety and clinical outcome of this technical. 
 
Material and Methods: 26 patients with stage T1-T2b NPC 
who suffered from locally residual lesion in nasopharyngeal 
cavity (All the tumors were less than 1 cm below the 
nasopharyngeal epithelium) after standard radical 
radiotherapy (70-74 Gy) ± platinum-based chemotherapy 
were further administrated by the 3D-CT based and 
endoscopical guided brachytherapy using the Foshan 
applicator or the standard nasopharyngeal applicator 
according the tumor location. The prescribed salvage dose of 
brachytherapy was 3.5 Gy/fraction, twice- daily with an 
interval of 6 h to a total dose of 7-14 Gy (one week apart) 
depending on the total dose of external beam radiotherapy. 
The total dose ranged from 81.8-85.6 Gy when transformed 
to EQD2 models, and the Pstem D1%< 60 Gy was restricted in 
planning. The primary endpoint was 1-, 3-year overall 
survival and secondary endpoints were: local control, distant 
metastasis and grade 3-4 adverse events. 
 
Results: The whole brachytherapy procedure was well 
tolerated under local anesthesia. 24 patients (92.3%) get 
complete response (CR) as confirmed by enhanced CT/MRI 
after 1-3 month after the brachytherapy. With a median 
follow-up time of 40 months, no serious complications or late 
sequelae occurred. The 1-, and 3-year overall survival, 
locoregional free survival, and distant-metastasis free 
survival rates were 96.2%, 80.8%, 92.3% and 84.6%, 
respectively. And the patients with early-T stage at initial 
diagnosis had 100% local control rate. 
 
Conclusion: Brachytherapy is of benefit to improve the local 
control of primary lesion of NPC with residual nasopharyngeal 
cavity involvement. It is a safe and effective approach for 
patients with poor tumor regression at the end of external 
beam radiotherapy for boosting the local irradiation dose.  
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Purpose or Objective: Total salvage Iodine-125 
brachytherapy (TS I-125-BT) is a potentially curative 
treatment strategy for localized prostate cancer (PCa) 
recurrences after radiotherapy. Prognostic factors influencing 
PCa-specific and overall mortality (PCaSM & OM) are not 
known. The objective was therefore to develop a 
multivariable, internally validated prognostic model for 
survival after TS I-125-BT. 
 
Material and Methods: Retrospectively, sixty-two TS I-125-BT 
patients were analyzed. These patients were treated from 
1993-2010 in the Netherlands. Multivariable Cox-regression 
was used to assess the influence of pre-salvage 
characteristics on PCaSM and OM. Missing data was handled 
by using multiple imputation (20 imputed sets). Internal 
validation was done using 500 bootstrap resamples of every 
imputed set. Discriminatory ability was quantified with the C-
statistic. Calibration plots were created to visually assess the 
